KR870700018A - 클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제 - Google Patents

클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제

Info

Publication number
KR870700018A
KR870700018A KR1019860700635A KR860700635A KR870700018A KR 870700018 A KR870700018 A KR 870700018A KR 1019860700635 A KR1019860700635 A KR 1019860700635A KR 860700635 A KR860700635 A KR 860700635A KR 870700018 A KR870700018 A KR 870700018A
Authority
KR
South Korea
Prior art keywords
drug
composition
glycerol
glycerol phosphatide
phosphatide
Prior art date
Application number
KR1019860700635A
Other languages
English (en)
Other versions
KR890004690B1 (ko
Inventor
필립 안토니 징크스
알렉산더 벨
프란츠 크사버 피셔
Original Assignee
원본미기재
라이커 라버러터리스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 라이커 라버러터리스, 인코포레이티드 filed Critical 원본미기재
Publication of KR870700018A publication Critical patent/KR870700018A/ko
Application granted granted Critical
Publication of KR890004690B1 publication Critical patent/KR890004690B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

내용 없음.

Description

클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (29)

1이상의 클로로플루오로카본 연무질 포사약, 글리세롤 포스파티드 및 약물로 구성되고, 이 약물이 당해 조성물에 용해되어지는 연무질 조성물.
제1항에 있어서, 상기 글리세롤포스파티드가 포스파티딜콜린, 포스파티딜에탄올아민, 포스파티딜이노시톨, 포스파티딜세린, 디포스파티딜글리세롤, 포스파티드산 및 그것의 혼합물로부터 선택된 조성물.
제2항에 있어서, 상기 글리세롤 포스파티드가 포스파티딜콜린인 조성물.
전술한 항들중 한항에 있어서, 상기 글리세롤 포스파티드가 정제되어진 조성물.
제1항 내지 제4항중 어느 한항에 있어서, 포사약 11, 글리세롤 포스파티드 및 약물로 구성되는 조성물.
전술한 항들중 어느 한항에 있어서, 글리세롤 포스파티드 : 포사약 11의 비가 0.01 내지 20:100인 조성물.
전술한 항들중 어느 한항에 있어서, 글리세롤 포스파티드 : 포사약 11의 비가 0.01 내지 10:100인 조성물.
전술한 항들중 어느 한항에 있어서, 글리세롤 포스파티드 : 포사약 11의 비가 0.01 내지 3:100인 조성물.
전술한 항들중 어느 한항에 있어서, 포사약 11,12,13,21,22,113,114,115 및 500으로부터 선택된 1이상의 포사약으로 구성되는 조성물.
전술한 항들중 어느 한항에 있어서, 약물:글리세롤 포스파티드의 비가 1 내지 500:100인 조성물.
전술한 항들중 어느 한항에 있어서, 약물:글리세롤 포스파티드의 비가 1 내지 30:100인 조성물.
전술한 항들중 어느 한항에 있어서, 약물:글리세롤 포스파티드의 비가 2 내지 10:100인 조성물.
전술한 항들중 어느 한항에 있어서, 가용화 공정을 향상시키기 위한 소량의 보조용매로 부가적으로 구성되는 조성물.
전술한 항들중 어느 한항에 있어서, 상기 약물이 베클로메타손 디프로피오네이트, 베타메타손 디프로피오네이트, 발러레이트와 그의 염기, 살부타몰 염기, 아트로핀 염기 및 프레드니솔론으로부터 선택된 조성물.
제1항 내지 제13항중 어느 한항에 있어서, 상기 약물이 포르모테롤 염기, 히드로클로라이드, 헤미설페이드 및 푸마레이트로부터 선택된 조성물.
제1항 내지 제13항중 어느 한항에 있어서, 상기 약물이 디아제팜, 로라제팜, 프로프라놀롤 히드로클로라이드, 히드로코르티손, 플루오시놀론 아세토나이트, 트리암시놀론 아세토나이드, 크실로메타졸린히드, 로클로라이드, 비톨테롤 메실레이트 및 라시코트톤으로부터 선택된 조성물.
전술한 항들중 어느 한항에 청구된 바와 같은 조성물로 충전된 가압연무질 팩.
클로로플루오로카본 연무질 포사약에서 극히 녹지 않는 용해도를 갖는 약물을 가용화시키는 방법에 있어서, 상기 약물을 유효량의 글리세롤 포스파티드의 존재하에 클로로플루오로카본 포사약에 혼합시켜서 구성되는 방법.
제18항에 있어서, 상기 글리세롤 포사파티드가 포스파티딜콜린, 포스파티딜에탄올아민, 포스파티딜이노시톨, 포스파티딜세린, 디포스파티딜글리세롤 및 포스파티드산으로부터 선택된 방법.
제18항에 있어서, 상기 글리세롤 포스파티드가 포스파티딜콜린인 방법.
제18항 내지 제20항중 어느 한항에 있어서, 상기 글리세롤 포스파티드가 정제되어진 방법.
제18항 내지 제19항중 어느 한항에 있어서, 포사약 11, 글리세롤 포스파티드 및 약물로 구성되고, 상기 혼합물이 교반하에 수행되어지는 방법.
제21항에 있어서, 글리세롤 포스파티드 : 포사약 11의 비가 0.01 내지 20:100인 방법.
제19항 내지 제21항중 어느 한항에 있어서, 포사약 11,12,13,21,22,113,114,115 및 500으로부터 선택된 1이상의 포사약으로 구성되는 방법.
제18항 내지 제24항중 어느 한항에 있어서, 상기 가용화 공정을 향상시키기 위한 소량의 보조용 매로 부가적으로 구성되는 방법.
제18항 내지 제25항중 어느 한항에 있어서, 상기 약물이 베크로 메타손 디프로피오네이트, 베타메타손 디프로피오네이트, 아세테이트, 발러레이트와 그의 염기, 살부타몰 염기, 아트로핀 염기 및 프레드니솔론으로부터 선택된 방법.
제18항 내지 제25항중 어느 한항에 있어서, 상기 약물이 포르모테롤 염기, 히드로클로라이드, 헤미설페이트 및 푸마레이트로부터 선택된 방법.
제18항 내지 제25항중 어느 한항에 있어서, 상기 약물이 디아제팜, 로라제팜, 프로프라놀롤히드로클로라이드, 히드로코르티손, 플루오시놀론 아세토나이드, 트리암시놀론 아세토나이드, 크실로메타릴린히드로클로라이드, 비톨테롤 메실레이트 및 라시코르톤으로부터 선택된 방법.
클로로 플루오로카본 연무질 포사약에서 극히 용해하지 않는 용해도를 갖는 약물을 가용화 시키는 공정에 있어서, 유효량의 글리세롤 포스파티드를 사용하는 것으로 구성하는 공정.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860700635A 1985-01-16 1986-01-02 약물을 함유하는 클로로 플루오로카본 연무질 포사약 조성물 KR890004690B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8501015 1985-01-16
GB858501015A GB8501015D0 (en) 1985-01-16 1985-01-16 Drug
PCT/GB1986/000001 WO1986004233A1 (en) 1985-01-16 1986-01-02 Drug-containing chlorofluorocarbon aerosol propellent formulations

Publications (2)

Publication Number Publication Date
KR870700018A true KR870700018A (ko) 1987-02-28
KR890004690B1 KR890004690B1 (ko) 1989-11-25

Family

ID=10572909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860700635A KR890004690B1 (ko) 1985-01-16 1986-01-02 약물을 함유하는 클로로 플루오로카본 연무질 포사약 조성물

Country Status (23)

Country Link
US (1) US4814161A (ko)
EP (1) EP0209547B1 (ko)
JP (1) JPH0811725B2 (ko)
KR (1) KR890004690B1 (ko)
AT (1) ATE56358T1 (ko)
AU (1) AU577663B2 (ko)
CA (1) CA1264297A (ko)
DD (1) DD241422A5 (ko)
DE (1) DE3674098D1 (ko)
DK (1) DK175346B1 (ko)
ES (1) ES8800037A1 (ko)
FI (1) FI90014C (ko)
GB (1) GB8501015D0 (ko)
GR (1) GR860066B (ko)
HU (1) HU196303B (ko)
IE (1) IE58703B1 (ko)
IL (1) IL77467A (ko)
NO (1) NO172727C (ko)
NZ (1) NZ214832A (ko)
PH (1) PH23529A (ko)
PT (1) PT81839B (ko)
WO (1) WO1986004233A1 (ko)
ZA (1) ZA8645B (ko)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
USRE36744E (en) * 1988-09-16 2000-06-20 Ribogene, Inc. Nasal administration of benzodiazepine hypnotics
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) † 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
ATE156704T1 (de) * 1989-12-05 1997-08-15 Ramsey Foundation Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
JPH05507090A (ja) * 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) * 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
WO1992006726A1 (en) * 1990-10-16 1992-04-30 Mayor Pharmaceutical Laboratories, Inc. Vitamin-mineral treatment methods and compositions
AU680568B2 (en) * 1990-10-16 1997-07-31 Mayor Pharmaceutical Laboratories, Inc. Vitamin-mineral treatment methods and compositions
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US6866839B2 (en) * 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9118830D0 (en) * 1991-09-03 1991-10-16 Minnesota Mining & Mfg Medical aerosol formulations
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
NZ246046A (en) * 1991-12-12 1995-12-21 Glaxo Group Ltd Aerosol comprising a particulate medicament in a fluorocarbon or chlorofluorohydrocarbon and a polar cosolvent
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ES2099415T3 (es) 1991-12-18 1997-05-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
US5618515A (en) * 1992-08-19 1997-04-08 Blistex Inc. Aerosol spray composition for the treatment of dermal burns by cooling and anesthetizing the wound and valved container for dispensing same
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
DK0735884T3 (da) * 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
EP0759744B1 (en) * 1994-05-13 2001-10-17 Aradigm Corporation Narcotic containing aerosol formulation
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030077228A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030190286A1 (en) * 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095927A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20040141923A1 (en) * 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050163719A1 (en) * 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20090162300A1 (en) * 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20050287075A1 (en) * 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136913A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20040136915A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
JP2002533379A (ja) * 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
US6303145B2 (en) 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6676930B2 (en) * 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) * 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
PT2630954T (pt) * 2002-03-20 2017-01-05 Civitas Therapeutics Inc Administração pulmonar de levodopa
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US20040234699A1 (en) 2003-05-21 2004-11-25 Alexza Molecular Delivery Corporation Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
WO2005037949A2 (en) * 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
US7540286B2 (en) * 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) * 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
CA2607391A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
US20060239935A1 (en) * 2005-04-23 2006-10-26 Boehringer Ingelheim International Gmbh Compositions for inhalation
CA2649895C (en) * 2006-04-19 2013-03-26 Novadel Pharma Inc. Stable hydroalcoholic oral spray formulations and methods
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US20080171089A1 (en) * 2006-12-22 2008-07-17 Blondino Frank E Stable anti-nausea oral spray formulations and methods
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
AU2008251370A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
US7985325B2 (en) * 2007-10-30 2011-07-26 Novellus Systems, Inc. Closed contact electroplating cup assembly
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB993702A (en) * 1961-11-10 1965-06-02 Takeda Chemical Industries Ltd An aerosol dispersing agent
US3551558A (en) * 1967-08-18 1970-12-29 Eisai Co Ltd Therapeutical aerosol composition and preparation thereof
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
GB2001334B (en) * 1977-07-19 1982-03-03 Fisons Ltd Pressurised aerosol formulation
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
AU527931B2 (en) * 1979-05-08 1983-03-31 Farmitalia Carlo Erba S.P.A. Substituted pyrido(1,2-a)pyrimidines
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug

Also Published As

Publication number Publication date
FI863730A0 (fi) 1986-09-15
AU5306486A (en) 1986-08-13
JPS62501906A (ja) 1987-07-30
IE860114L (en) 1986-07-16
PT81839A (en) 1986-02-01
ES550891A0 (es) 1987-10-16
FI863730A (fi) 1986-09-15
DK440386D0 (da) 1986-09-15
NZ214832A (en) 1988-02-29
KR890004690B1 (ko) 1989-11-25
EP0209547A1 (en) 1987-01-28
PH23529A (en) 1989-08-25
DD241422A5 (de) 1986-12-10
US4814161A (en) 1989-03-21
ES8800037A1 (es) 1987-10-16
PT81839B (pt) 1988-05-27
EP0209547B1 (en) 1990-09-12
AU577663B2 (en) 1988-09-29
NO172727C (no) 1993-09-01
ATE56358T1 (de) 1990-09-15
FI90014B (fi) 1993-09-15
NO863683D0 (no) 1986-09-15
FI90014C (fi) 1993-12-27
JPH0811725B2 (ja) 1996-02-07
HUT42938A (en) 1987-09-28
NO863683L (no) 1986-09-15
WO1986004233A1 (en) 1986-07-31
DK440386A (da) 1986-09-15
DE3674098D1 (de) 1990-10-18
IL77467A (en) 1990-12-23
GB8501015D0 (en) 1985-02-20
HU196303B (en) 1988-11-28
NO172727B (no) 1993-05-24
DK175346B1 (da) 2004-08-30
IE58703B1 (en) 1993-11-03
GR860066B (en) 1986-04-24
CA1264297A (en) 1990-01-09
ZA8645B (en) 1986-10-29

Similar Documents

Publication Publication Date Title
KR870700018A (ko) 클로로플루오로카본 연무질 포사약 조성물을 함유하는 약제
DE68924540T3 (de) Medizinische Aerosolformulierungen.
ATE34078T1 (de) Arzneiform zur oralen verabreichung sowie verfahren zu deren herstellung durch gefriertrocknen einer oel-in-wasser-emulsion.
NZ240237A (en) An aerosol formulation (free of surfactant) for treatment of asthma comprising: a hydrofluorocarbon propellant, ethanol, and beclomethasone 17,21 dipropionate; preparation thereof
CZ288146B6 (en) Pharmaceutical aerosol preparation, process of its preparation and use
KR890700036A (ko) 비내 투여용 제제 및 그 제조방법
PT98890A (pt) Processo para a preparacao de composicoes farmaceuticas antiemeticas contendo uma mistura de ondansetron com um agente antiemetico ou tranquilizante
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
EP0536204A1 (en) APPLICATION OF SOLUBLE FLUORINE SURFACTANTS FOR THE PRODUCTION OF AEROSOL PREPARATIONS WITH DOSED DELIVERY.
EP0602181A1 (en) Medicinal aerosol formulations
JPS5716818A (en) Steroid fatty emulsion
EP0409936B1 (de) Verfahren zur herstellung wässriger mischmicellösungen
GB2068227A (en) Topical ointment
NZ187894A (en) Pressure pack formulations of lecithin or a sorbitan or sorbitol ester
ES2230066T3 (es) Aerosoles dosificadores con isobutano como propelente.
DE10260882B4 (de) Dosieraerosole mit Sojalecithin als oberflächenaktiver Substanz und dessen Verwendung
KR910015287A (ko) 의약 유제
SE9402455D0 (sv) Bilayer preparations

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19961112

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee